Data / Form D filings / EXAGEN INC.
EXAGEN INC.: Form D filings
EXAGEN INC., a biotechnology company in Vista, CA, filed 25 Form D notices with the SEC between 2009 and 2019. The latest, on February 1, 2019, reports $6.6 million sold of a $16 million offering to 4 investors.
Find out what EXAGEN INC. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1261 Liberty Way, Suite C, Vista, CA, 92081
- Phone
- (760) 560-1501
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1274737
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 1, 2019 | New notice | $16,000,000 | $6,586,411 | $9,413,589 | 4 | Jan 2, 2019 | sec.gov |
| May 18, 2017 | New notice | $13,179,796 | $3,749,993 | $9,429,803 | 4 | May 4, 2017 | sec.gov |
| Apr 10, 2017 | New notice | $1,314,500 | $1,314,500 | $0 | 5 | Apr 6, 2017 | sec.gov |
| Mar 9, 2017 | New notice | $1,453,000 | $1,453,000 | $0 | 4 | Feb 24, 2017 | sec.gov |
| Feb 1, 2017 | New notice | $995,889 | $995,889 | $0 | 4 | Jan 27, 2017 | sec.gov |
| Dec 19, 2016 | New notice | $995,889 | $995,889 | $0 | 4 | Dec 12, 2016 | sec.gov |
| Nov 10, 2016 | New notice | $995,889 | $995,889 | $0 | 4 | Nov 7, 2016 | sec.gov |
| Oct 11, 2016 | New notice | $995,889 | $995,889 | $0 | 4 | Oct 5, 2016 | sec.gov |
| Aug 30, 2016 | New notice | $1,000,000 | $1,000,000 | $0 | 4 | Aug 26, 2016 | sec.gov |
| Jun 24, 2016 | New notice | $2,100,000 | $2,100,000 | $0 | 6 | Jun 21, 2016 | sec.gov |
| Jan 26, 2016 | New notice | $30,852,618 | $16,817,541 | $14,035,077 | 13 | Jan 19, 2016 | sec.gov |
| Oct 21, 2015 | New notice | $4,500,000 | $2,999,766 | $1,500,234 | 4 | Oct 9, 2015 | sec.gov |
| Jul 6, 2015 | New notice | $3,000,000 | $3,000,000 | $0 | 3 | Jul 2, 2015 | sec.gov |
| Apr 1, 2015 | New notice | $4,547,811 | $1,818,767 | $2,729,044 | 8 | Feb 19, 2015 | sec.gov |
| Jul 21, 2014 | New notice | $3,950,000 | $3,950,000 | $0 | 12 | Jul 10, 2014 | sec.gov |
| Oct 15, 2013 | New notice | $5,016,977 | $5,016,977 | $0 | 11 | Oct 4, 2013 | sec.gov |
| Nov 1, 2012 | New notice | $679,407 | $123,745 | $555,662 | 5 | Oct 18, 2012 | sec.gov |
| Sep 11, 2012 | New notice | $5,306,834 | $5,306,834 | $0 | 7 | Sep 4, 2012 | sec.gov |
| Dec 22, 2011 | New notice | $24,709,488 | $11,986,707 | $12,722,781 | 9 | Dec 19, 2011 | sec.gov |
| Nov 18, 2011 | New notice | $1,000,000 | $1,000,000 | $0 | 4 | Nov 4, 2011 | sec.gov |
| Sep 27, 2011 | New notice | $6,450,000 | $4,910,423 | $1,539,577 | 8 | Sep 13, 2011 | sec.gov |
| Jun 29, 2011 | New notice | $5,799,998 | $4,910,490 | $889,508 | 8 | Jun 14, 2011 | sec.gov |
| May 11, 2011 | Amendment | $5,427,984 | $5,427,984 | $0 | 17 | Oct 6, 2010 | sec.gov |
| Oct 25, 2010 | New notice | $3,548,404 | $1,999,995 | $1,548,409 | 10 | Oct 6, 2010 | sec.gov |
| May 26, 2009 | New notice | $2,000,000 | $1,000,000 | $1,000,000 | 15 | May 8, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Daniel C. Burrell | Director | |
| Thierry L.L. Dervieux | Executive Officer | |
| Fortunato R. Rocca | Executive Officer, Director | |
| Ebetuel R. Pallares | Director | |
| James L.L. Tullis | Director | |
| Kamal L.L. Adawi | Executive Officer | |
| Arthur L.L. Weinstein | Director | |
| Brian R. Birk | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Jan 28, 2019 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what EXAGEN INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.